| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCL7C |
| Uniprot No | Q8WUZ0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-217aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMAGRTVRAETRSRAKDDIKKVMATIEK VRRWEKRWVTVGDTSLRIFKWVPVVDPQEEERRRAGGGAERSRGRERRGR GASPRGGGPLILLDLNDENSNQSFHSEGSLQKGTEPSPGGTPQPSRPVSP AGPPEGVPEEAQPPRLGQERDPGGITAGSTDEPPMLTKEEPVPELLEAEA PEAYPVFEPVPPVPEAAQGDTEDSEGAPPLKRICPNAPDP |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCL7C重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: "BCL7C is a novel component of the SWI/SNF chromatin remodeling complex and regulates cell proliferation"
**作者**: Zhang X, et al.
**摘要**: 该研究首次报道了BCL7C作为SWI/SNF染色质重塑复合体的新亚基，通过重组蛋白表达验证其与复合体核心蛋白的相互作用，并发现其通过调控细胞周期相关基因影响肿瘤细胞增殖。
2. **文献名称**: "Structural and functional characterization of the BCL7C subunit in the BAF complex"
**作者**: Wang L, et al.
**摘要**: 利用重组BCL7C蛋白进行体外结合实验和晶体结构分析，揭示了BCL7C在BAF复合体中的构象变化及其对DNA结合能力的调控作用，为理解其在表观遗传调控中的功能提供结构基础。
3. **文献名称**: "BCL7C interacts with cohesin to maintain chromatin organization and suppress oncogenesis"
**作者**: Johnson DS, et al.
**摘要**: 通过重组BCL7C与cohesin复合体蛋白的共纯化实验，证实两者在维持三维基因组结构中的协同作用，并证明BCL7C缺失导致染色质不稳定，促进淋巴瘤发生。
注：以上文献信息为模拟示例，实际文献需通过PubMed/Google Scholar检索确认。
**Background of BCL7C Recombinant Protein**
BCL7C (B-cell lymphoma 7 protein family member C) is a subunit of the SWI/SNF chromatin remodeling complex, specifically the BAF (BRG1/BRM-associated factor) complex, which regulates gene expression by altering chromatin structure. It belongs to the BCL7 protein family, which includes BCL7A, BCL7B, and BCL7C. These proteins are implicated in diverse cellular processes, including DNA repair, differentiation, and tumor suppression. BCL7C, encoded by the *BCL7C* gene on chromosome 16q23.3. is less characterized compared to its paralogs but shares structural features, such as a conserved N-terminal domain critical for protein interactions.
Dysregulation of BCL7C has been linked to cancers, particularly hematological malignancies and solid tumors. For instance, deletions or mutations in *BCL7C* are observed in subsets of non-Hodgkin lymphomas and neuroblastomas, suggesting a potential tumor-suppressive role. The BAF complex, including BCL7C, often undergoes subunit-specific alterations in cancer, leading to aberrant transcriptional programs.
Recombinant BCL7C protein is engineered for functional and structural studies, typically expressed in *E. coli* or mammalian systems with tags (e.g., His, GST) for purification. Its production enables investigations into BCL7C’s role in chromatin remodeling, protein-protein interactions (e.g., with other BAF subunits like SMARCA4/BRG1), and mechanisms underlying its tumor-suppressive functions. Researchers also utilize recombinant BCL7C to explore its potential as a therapeutic target or biomarker in diseases linked to SWI/SNF dysfunction.
Overall, BCL7C recombinant protein serves as a vital tool for unraveling the molecular basis of chromatin regulation and its implications in health and disease.
×
